1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
6Chan Henry.Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir,a randomized trial[J].Annals of Internal Medicine,2007,147(11):745-754.
7Hsu YS,Chien RN,Yeh CT.Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B[J].Hepatology,2002,35(6):1522-1527.
8Lin SM.Interferon therapy in HBeAg positive chronic hepatitis reduees progression to cirrhosis and hepatocellulat carcinoma[J].Journal of Hepatology,2007,46(1):45-52.
1Fabrizi F,Dixit V,Martin P.Meta-analysis:the adjuvantrole of thymopentin on immunological response to hepati-tis B virus vaccine in end-stage renal disease [J].AlimentPharmacol Ther,2006,23(11):1559-1566.
2Wang GQ,Ding YP,Dong YH.et al.Telbivudine treatmentis associated with high hepatitis B e antigen seroconver-sion and immune modulatory effects in chronic hepatitis Bpatients[J]J Viral Hepat,2013,20(Suppl 1):9-17.
3Han Z,Shi Y,Zhu J,et al.Forty-eight-week retrospectivestudy of telbivudine and lamivudine treatment in patientswith hepatitis B-related cirrhosis[J].J Viral Hepat,2013,20(Suppl l):58-64.
